пятница, 29 июля 2016 г.

Merck posts strong 2Q numbers, while building for long term

Merck posts strong 2Q numbers, while building for long term


Drugmaker Merck & Co., focused heavily on its long-term future as it builds sales of crucial new medicines Keytruda for cancer and Zepatier for hepatitis C, still posted a big jump in second-quarter profit thanks to slightly higher sales and more cost cutting. The drugmaker is transitioning to a hoped-for new growth cycle fueled by those recently launched, potential blockbuster drugs.



from Biotech News